QP
Therapeutic Areas
Cadrenal Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CAD-1005 | Heparin-Induced Thrombocytopenia (HIT) | Phase 3-ready |
| Tecarfarin | Anticoagulation in End-Stage Kidney Disease (ESKD) with Atrial Fibrillation (AF) | Phase 3-ready |
| Frunexian | Anticoagulation in acute/critical care settings (e.g., complex cardiac surgery) | Clinical-stage |
| Second-generation 12-LOX oral therapeutics | Not specified (Platform expansion) | Pre-clinical/Discovery |